Kenvue Inc. (NYSE: KVUE) is a prominent player in the consumer health industry, offering a range of products that cater to personal health and wellness. The company operates in a competitive market, with rivals like Procter & Gamble and Johnson & Johnson. Recently, Jefferies downgraded Kenvue from a Buy to a Hold rating, reflecting a more cautious outlook on the stock.
The downgrade by Jefferies comes as Kenvue's stock price stands at $17.20. This aligns with the consensus among eighteen brokerages, as highlighted by Marketbeat, which also rate the stock as a Hold. Among these, twelve analysts recommend holding, five suggest buying, and one strongly advises buying. The average 1-year target price is approximately $20.23.
Other analysts have also shown caution. Johnson Rice maintains a "neutral" rating, while Citigroup lowered its price target from $20.00 to $17.00, keeping a "neutral" stance. Canaccord Genuity Group revised their price objective from $26.00 to $15.00, reaffirming a "hold" rating. These adjustments indicate a tempered outlook on Kenvue's future performance.
Kenvue's stock has seen fluctuations, with a recent decrease of 0.81%, or $0.14, in its price. The stock has traded between $17.175 and $17.44 today. Over the past year, it reached a high of $25.17 and a low of $14.02. The company's market capitalization is approximately $32.96 billion, with a trading volume of 42.63 million shares today.
